Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Realty stocks lead the gains
Thu, 18 Sep Closing

After trading in the positive territory during post noon trading session, the Indian equity markets gained further ground and closed the day in the green. While the BSE Sensex today closed higher by 481 points, the NSE-Nifty closed higher by 139 points. Midcaps and Smallcaps too closed on a strong note today. While the BSE Mid Cap index closed higher by 1.8%, the BSE Small Cap index was up by 2.7%. Realty and consumer durable stocks were the biggest gainers today.

As regards global markets, Asian indices also closed strong today with the exception of Korea and Hong Kong. The rupee was trading at Rs 60.95 to the dollar at the time of writing.

Mining stocks ended the day on a strong note today. Hindustan Zinc and MMTC Ltd were the biggest gainers. In order to ensure interrupted fuel supply to power plants, the government has directed Coal India to cut the quantity of coal it sells via auctions. It may be noted that Coal India sells coal in the open market as well as via auctions. The auction route is beneficial since it fetches higher realizations. However, this raises the cost of power and reduces the quantity of sales that happen in open market. As a result, the government has asked Coal India to cut the quantity of coal sold through the auction route. It is believed that loss of revenues due to lower quantum of sales via the auction route may prompt the company to raise the prices. If prices indeed increase it may attract investor interest into the stock.

Pharma stocks have closed the day on a positive note. The gains were led by the stocks of Dr. Reddy's, Divis Laboratories and Dishman Pharma, each of whom ended the day with gains upwards of 3%. As per a leading business daily, the export of pharmaceutical products from India is set to cross the Rs 1 trillion mark in value terms during FY15. This is up from Rs 900 bn during FY14. If this level of exports is achieved this year, it will in effect mean that pharmaceutical exports will have recorded a growth of 15% this year in FY15. The majority of the export revenues are being expected to come from formulations this financial year.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty stocks lead the gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.